Clinical Trial Update: Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

View source ↗

Summary

A completed health-economics analysis comparing rivaroxaban to vitamin K antagonists for atrial fibrillation. It assesses potential event-related cost savings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Atrial Fibrillation | Status: COMPLETED